Champions Oncology, INC

Champions Oncology announced record annual revenue of $59.4 million and positive Adjusted EBITDA for the fiscal year ended April 30, 2026, alongside a 12% increase in fourth-quarter revenue.

Champions Oncology appointed Brian Alexander, MD, MPH, to its board following Philip Breitfeld’s resignation, reinforcing a strategy to expand AI- and data-driven oncology R&D.

Champions Oncology announced its third quarter fiscal 2026 financial results, reporting record study service revenue of $16.6 million, up 32% year-over-year, despite a modest decline in total revenue.

Champions Oncology announced its second quarter fiscal 2026 financial results, reporting an 11% increase in total revenue to $15 million and record quarterly service revenue.

Champions Oncology, Inc. announced the results of its Annual Meeting of Stockholders, where all director nominees were re-elected, EisnerAmper LLP was ratified as the independent auditor, and executive compensation was approved.

Champions Oncology reported first-quarter fiscal 2026 revenue of $14.0 million and adjusted EBITDA of $60,000, alongside the appointment of Rob Brainin as CEO.

Champions Oncology reported a net loss for the third quarter and nine months ended January 31, 2026, driven by a significant decline in TOS data license revenue and increased operating expenses.

Champions Oncology reported a net loss for the six months ended October 31, 2025, despite revenue growth, driven by increased investments in R&D and its data licensing platform.

Champions Oncology, Inc. reported a net loss of $0.44 million for the first fiscal quarter of 2026, a significant decline from a $1.31 million net income in the prior year, driven by increased R&D and operating costs.

Champions Oncology's Q3 2025 revenue increased by 41.8% year-over-year, driven by growth in pharmacology services and data license sales.

Champions Oncology reports a net income of $2.041 million for the six months ended October 31, 2024, a significant turnaround from a net loss of $4.637 million in the same period last year, driven by a 14.2% increase in oncology services revenue.

Champions Oncology reports a net income of $1.3 million for the quarter ended July 31, 2024, a significant turnaround from a net loss in the same period last year, with revenue increasing by 11.9%.

Champions Oncology, Inc. announced its fiscal year 2026 results, reporting a 4.4% increase in revenue to $59.4 million, driven by growth in pharmacology services, despite a net loss for the year.

Champions Oncology, a technology-enabled research organization, announced a significant financial turnaround in fiscal year 2025, achieving net income and positive cash flow from operations driven by increased revenue from research services and new data licensing.

Champions Oncology's annual report reveals a net loss of $7.3 million for fiscal year 2024 and raises substantial doubt about the company's ability to continue as a going concern.

Champions Oncology, Inc. CEO Robert Lawrence Brainin received 700,000 stock options with various performance and time-based vesting conditions.

Robert L. Brainin, a Director at Champions Oncology, Inc., was granted a series of stock options with varying exercise prices and vesting schedules.

Champions Oncology Director Philip P. Breitfeld acquired 13,790 options to purchase common stock at an exercise price of $6.80, vesting over 12 months.

Champions Oncology Director David Sidransky was granted 21,216 stock options with an exercise price of $6.8, vesting over 12 months starting November 5, 2025.

Champions Oncology Director Daniel Mendelson was granted options to purchase 13,790 shares of common stock at an exercise price of $6.80 per share.

Champions Oncology Director and 10% owner Scott R. Tobin acquired 25,460 stock options with an exercise price of $6.80, vesting over 12 months.

Champions Oncology, Inc. announces its Annual Meeting of Stockholders for October 16, 2025, to address director elections, auditor ratification, and executive compensation.

Champions Oncology, Inc. announces its Annual Meeting of Stockholders on October 16, 2025, to elect directors, ratify auditors, and approve executive compensation.

Champions Oncology announces its annual stockholders meeting to be held on October 14, 2024, outlining proposals for director elections, auditor ratification, and executive compensation.

Champions Oncology will hold its annual stockholders meeting on October 14, 2024, to elect directors, ratify the appointment of its accounting firm, and vote on executive compensation.

Tocqueville Asset Management L.P., along with Taubenpost Capital L.P., Taubenpost Capital LLC, and Donald Wang, have disclosed a collective passive beneficial ownership of 4.4% in Champions Oncology, Inc. as of December 31, 2024.